title: [Effects of folic acid supplementation on hyperhomocysteinemia in CAPD patients: effects on unsaturated fatty acids].
abstract: Hyperhomocysteinemia has been recognized as one of the risk factors for atherosclerosis and premature vascular disease. Patients on dialysis and end-stage renal disease also manifest high plasma concentrations of homocysteine. We performed this study to evaluate the effects of folic acid supplementation on hyperhomocysteinemia in CAPD patients. Twenty-three CAPD patients (8 males, 15 females, 49.1 +/- 14.2-years-old) dialyzed for 22.7 +/- 19.2 months participated in the study. Daily 5-mg doses of folic acid supplementation for 4 weeks significantly reduced plasma concentrations of total homocysteine (p < 0.01) and serine (p < 0.001). This observation suggests that the reduction of plasma concentrations of total homocysteine results from activation of homocysteine remethylation to methionine. On the other hand, folic acid supplementation also revealed significant correlations between changes in serum concentrations of both dihomo-gamma-linolenic acid and arachidonic acid and changes in plasma concentrations of total homocysteine (r = -0.517, p < 0.05, r = -0.451, p < 0.05, respectively). In addition, serum concentrations of both dihomo-gamma-linolenic acid and arachidonic acid in 11 CAPD patients with hyperhomocysteinemia (> or = 35 micromol/litter) were significantly lower than those of 12 CAPD patients with normohomocysteinemia (< 35 micromol/litter) (p < 0.05, p < 0.05, respectively). Serum concentrations of both dihomo-gamma-linolenic acid and arachidonic acid in CAPD patients with hyperhomocysteinemia increased significantly (p < 0.01, p < 0.05, respectively) and reached similar levels of CAPD patients with normohomocysteinemia, while plasma concentrations of total homocysteine decreased after folic acid supplementation. These findings suggest that correction of hyperhomocysteinemia in patients on dialysis produces an increase in unsaturated fatty acids.
authors.affiliation: Saitama Medical Center, Fourth Department of Internal Medicine, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Hirose
authors.forename: S
authors.initials: S
authors.lastname: Kim
authors.forename: A
authors.initials: A
authors.lastname: Matsuda
authors.forename: Y
authors.initials: Y
authors.lastname: Itakura
authors.forename: O
authors.initials: O
authors.lastname: Matsumura
authors.forename: H
authors.initials: H
authors.lastname: Tamura
authors.forename: R
authors.initials: R
authors.lastname: Nagasawa
authors.forename: T
authors.initials: T
authors.lastname: Mitarai
authors.forename: K
authors.initials: K
authors.lastname: Isoda
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D005231:Fatty Acids, Unsaturated / Q000097:blood*; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory
chemical_list: D005231:Fatty Acids, Unsaturated; D006710:Homocysteine; D005492:Folic Acid